Validating the Architecture
We are systematically de-risking the NBMods platform through rigorous internal validation programs, demonstrating our modular CMC framework's capacity to bypass tranditional manufacturing bottleneck and accelerate commercialization
Validating Versatility
Next-Generation RSV
The Challenge: Traditional platforms fail when forced to present complex, multivalent topologies, resulting in structural instability.
The Validation: We selected RSV as a lead validation target because it demands exceptionally high structural fidelity. By successfully engineering multivalent RSV candidates using optimized short and extended linkers, we validate the platform’s capacity to maintain absolute structural integrity under complex combinatorial loads.
The Implication: Partners can confidently load complex, multi-antigen cargoes onto the NBMods scaffold without triggering exponential instability.
Validating Speed
Updatable Influenza
The Challenge: Rigid manufacturing processes force a strict product-process coupling, causing response times to lag behind evolving viral threats.
The Validation: Influenza serves as the ultimate stress test for our platform's zero-friction iteration. By rapidly swapping seasonal antigenic cargoes without requiring a fundamental redesign of the nanoparticle scaffold or downstream purification, we validate the true plug-and-play agility of our framework.
The Implication: Partners can deploy our platform to pivot production instantly, drastically compressing the timeline from sequence identification to viable candidate.
Validating Precision & Scalability
Synthetic Diagnostics
The Challenge: The diagnostic supply chain is bottlenecked by a reliance on costly monoclonal antibodies, mammalian cell culture, and viral propagation.
The Validation: The structural precision of the NBMods platform translates directly into synthetic immunoreagents. By leveraging our multivalent polytope displays—produced with high efficiency in E. coli—we achieve exceptional specificity and sensitivity profiles without the overhead of traditional biologics.
The Implication: The platform is not restricted to long-cycle therapeutics; it offers a rapid, highly scalable architecture for deploying advanced diagnostic kits for emerging infectious diseases.
Validating Precision & Synergy
Targeted Viral Neutralization
The Challenge: Conventional antibody-based therapeutics (ABTs) are expensive to scale and struggle to maintain neutralizing efficacy against rapidly mutating viral variants.
The Validation: We engineered the NBMods platform to display high-affinity, AI-designed minibinders targeting SARS-CoV-2. By achieving a "dual-display" nanoparticle that simultaneously presents 20 integrated binder domains, we demonstrated synergistic binding activity with 400X-3000X higher neutralizing potencies, outperforming benchmark monoclonal antibodies.
The Implication: The platform is a potent, scalable alternative to traditional monoclonal antibodies, capable of seamlessly integrating next-generation AI-guided binders for immediate therapeutic deployment.
Advance the Pipeline with Us
Whether you are an investor looking to accelerate our path, or a strategic partner interested in our lead respiratory or diagnostic targets, we are ready to scale.